Chloroprocaine Injection [Clorotekal]

Phase 3

Chloroprocaine Injection [Clorotekal] is one of 2 therapeutic programs targeting Knee Arthroscopy. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Knee ArthroscopyNot yet recruiting

Knee ArthroscopyPhase 3

Not yet recruiting

Competition

Competitive Landscape

2 competitors in Knee Arthroscopy

#DrugCompanyPhaseTrials

Decadron

AAspen Global Incorporated

Phase 3

1 2

Chloroprocaine Injection [Clorotekal]

CCMC Ambroise Paré

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 3Not yet recruiting

Knee Arthroscopy

NCT07674576

Clinical

Trials by Indication[1]

Knee Arthroscopy1 trial

Efficacy of Intravenous Dexamethasone in Prolonging the Duration of Spinal Anesthesia With Chloroprocaine in Knee Arthroscopy: a Double-blind, Randomized, Controlled Trial

Not yet recruiting·CCMC Ambroise Paré·Phase 3·NCT07674576·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Chloroprocaine Injection [Clorotekal]. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Chloroprocaine Injection [Clorotekal]. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — CMC Ambroise Paré company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: CCMC Ambroise Paré

Chloroprocaine Injection [Clorotekal]

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Knee Arthroscopy1 trial

References

Drug Info

Quick Facts

Related News